Abstract: Antibiotic resistance is a major global health concern. There is a significant and urgent need for the development of novel antimicrobials to tackle the increasing incidence of antibiotic resistance. Recently, phenylglyoxamide-based small molecular antimicrobial peptide mimics have been identified as potential new leads to treat bacterial infection. Here, we describe the synthesis of novel phenylglyoxamide derivatives via the ring-opening reaction of N-sulfonylisatins with primary amines, followed by conversion into hydrochloride (HCl), quaternary ammonium iodide or guanidine salts. The antibacterial activity of the compounds against Staphylococcus aureus was evaluated in vitro by a disk diffusion assay and a minimum inhibitory concentration (MIC) assay. Structure-activity relationship studies revealed that a 5-bromo-substituent at the phenyl ring, octyl group appended to the ortho sulfonamide group or a guanidine hydrochloride salt as the terminal group significantly contributed to potency. The most potent compound in this study, the guanidine salt 35d, exhibited an MIC value of 12 µM. The most active compounds induced an increase in membrane conduction, suggesting that they are potential antimicrobial pore-forming agents. The compounds had therapeutic indices ranging from 0.8 to 15. Overall, the results identified 35d as a new lead antimicrobial compound that possesses an acceptable therapeutic window.
Introduction
Infectious diseases caused by bacteria are one of the leading causes of death worldwide. [1] The discovery of the powerful bactericidal agent, beta-lactam (penicillin), in the 1930s provided an effective strategy to treat bacterial infection. [2] Different classes of antibiotics target different metabolic processes in bacteria, such as inhibition of bacterial cell wall synthesis, protein synthesis, DNA and RNA synthesis, fatty acids biosynthesis, folate synthesis, or depolarizing bacterial cell membrane potentials. [3] However, the use of conventional antibiotics can exert selective survival pressure on bacteria, leading to the development of drug resistance. The most common antibiotic resistance mechanism is the enzymatic inactivation of antibiotics, whereby metabolic enzymes produced by bacteria metabolise antibiotics into their inactive form. For instance, beta-lactam antibiotics are inactivated by beta-lactamase enzymes, which hydrolyse the amide group and cleave the beta-lactam ring. [4] Other antibiotic resistance mechanisms involve mutations at the binding sites so that the antibiotics has reduced affinity, or physical removal of the antibiotic from the bacterial cell by efflux pumps. [5] The misuse and overuse of antibiotics has accelerated the development of antibiotic resistance. [6] Moreover, with typical antibiotic development strategies relying heavily on merely modifying the periphery of existing antibiotic scaffolds, resistance to one antibiotic can rapidly spread to other antibiotics within the same class as they share a common core. [7] Antibiotic-resistant bacteria cause more than 23,000 deaths in the US every year. [8] Alarmingly, multi-drug resistant bacterial strains have emerged that are resistant to all known antibiotics. [9] Therefore, there is an urgent need to develop novel and efficacious therapies to treat bacterial infection, particularly those caused by drug-resistance strains.
Antimicrobial peptides (AMPs) are naturally occurring amphipathic peptides found in most living organisms, including humans. [10] They play an important role as the first line of defence in our immune system and protect us against a wide variety of pathogenic organisms, such as bacteria, fungi, protozoa, yeast and viruses. [11] AMPs are typically 12 to 50 amino acids in length and contain both hydrophilic (cationic) and hydrophobic residues.
[10a] They possess rigid secondary alpha-helix or betasheet structures with the hydrophilic cationic residues located on one face of the molecule and hydrophobic residues on the opposite face. [1, 10a, 11a, 12] Unlike traditional antibiotics, AMPs do not act via enzyme or receptor interactions. Instead, they kill pathogens by disrupting their membrane integrity, causing the leakage of cellular components or the loss of membrane potential, both resulting in cell death. [13] The ability of AMPs to disrupt membranes is predominately attributed to their facially amphiphilic structure.
[11a] The hydrophilic cationic residues on one face of the AMP initially bind electrostatically to the negativelycharged bacterial cell membrane. Once the AMP is bound, the hydrophobic residues on the opposite face assist in the insertion of the molecule into the bacterial cell membrane, causing the formation of pores in the bacterial cell membrane.
[11a, 12, 14] As AMPs kill bacteria via disrupting bacterial cell membranes, a complete restructuring of the bacterial outer cell membrane would be required for bacteria to develop resistance to AMPs. [11a, 13c] More importantly, AMPs have a high degree of selectivity towards bacterial cells over human cells, which can be attributed to the difference in the lipid composition between the two types of cell membranes. [15] While the extracellular side of the human lipid bilayer is mainly composed of zwitterionic phospholipids such as phosphatidylcholine with only a minute amount of negativelycharged lipids, the bacterial cell membrane contains a significant portion of negatively-charged lipids, increasing their affinity towards AMPs.
[13b, [15] [16] AMPs have thus attracted attention as potential therapeutic agents to combat bacterial infection that are resistant to conventional antibiotics.
Although AMPs can exhibit potent and selective antibacterial activity, they have several drawbacks. Firstly, the synthesis of AMPs involves a high manufacturing cost. Due to the antibacterial nature of AMPs, it is difficult to use bacterial fermentation methods for synthesis. Current production methodologies are based on solid-phase peptide synthesis, which requires expensive precursor components and extensive purification, but only produces AMPs in low yield.
[17] Furthermore, AMPs are susceptible to protease hydrolysis. Proteases in the serum can cleave the peptide bonds in AMPs, reducing the metabolic stability of AMPs in vivo.
[18] The drawbacks of AMPs have stimulated the development of AMP mimics, such as α-peptides and β-peptides. [19] In addition, several small molecule AMP mimics (e.g. 1 and 2) have shown high antimicrobial activities against a variety of bacterial strains (Figure 1 ). [15, 20] LTX-109 3 is now in Phase-II clinical trials for the topical treatment of multi-drug resistant Gram-positive and Gram-negative bacteria.
[21]
N-Aryl, N-acyl or N-sulfonylisatins 4 ( Figure 2 ) can undergo ring-opening reaction with alcohols and amines to yield the corresponding phenylglyoxamide. [22] Recently, our research group has reported that N-naphthoyl-phenylglyoxamide derivatives 5 (Figure 2 ), possess moderate to high antibacterial activities against the common bacterial pathogens Staphylococcus aureus and Pseudomonas aeruginosa.
[22b] These phenylglyoxamides can be synthesised by the ring-opening reaction of N-sulfonylisatin with amines. As the effect of varying the N-substituent appended to ortho amino group on the activity of these compounds has not been explored, it is of great interest to synthesise novel N-sulfonyl-phenylglyoxamide derivatives as potential antibacterial agents. Chemical structures of AMP mimics 1-2 and LTX-109 3. [15, 20a, 21b] .
In this study, we report the synthesis of novel N-sulfonylphenylglyoxamide derivatives as small molecular AMP mimics. First, a panel of N-sulfonylisatins were synthesized via a simple and time-efficient method. Subsequently, the N-sulfonylisatins were ring-opened with diamines (N,N-dimethylethane-1,2-diamine or N,N-dimethylpropane-1,3-diamine) to give the corresponding phenylglyoxamide derivatives. Finally, these were converted into their hydrochloride or iodide salts to give the desired AMP mimics. In addition, N-octanesulfonylisatin and Nnaphthalenesulfonylisatin were also ring-opened with tert-butyl N-(3-aminopropyl)carbamate followed by installation of the guanidine moiety to furnish AMP mimics with an alternative cationic group.
The N-sulfonyl-phenylglyoxamide derivatives are amphipathic in nature due to the presence of both the hydrophobic groups at the N-sulfonyl position, and the hydrophilic ammonium or guanidine hydrochloride salts at the end of the glyoxamide chain (Figure 3 ). The synthesised compounds were evaluated for their antimicrobial potency against two common bacterial pathogens S. aureus and P. aeruginosa. Selected analogues with high antibacterial activity were tested for their ability to disrupt bacterial membrane integrity using tethered bilayer lipid membranes. Finally, their cytotoxicity against normal mammalian cells was also evaluated by using the Alamar Blue assay. 
Results and Discussion

Synthesis
Initially, the synthesis of N-sulfonylisatins followed a modified version of the procedure described by Chin et al. in 2002 , [23] in which isatin 6 was converted into its sodium salt by stirring with 1.2 equivalents of sodium hydride in dimethylformamide (DMF) at 0 °C for 20 min under a nitrogen atmosphere. An appropriate sulfonyl chloride was then added dropwise with stirring to the purple reaction mixture. After 18 h of stirring at room temperature, thin layer chromatography (TLC) confirmed the formation of product. The orange reaction mixture was poured into an icewater mixture and the precipitate was filtered to give an orange solid. However, after washing the crude solid with methanol, only poor yields (0-17%) of the N-sulfonylisatin products were obtained.
A modified version of the synthetic scheme described by Chung et al. in 2003 was then attempted in the synthesis of Nsulfonylisatins. [24] This method utilises milder reaction condition, and was reported to produce a moderate to high yield of the product in a time-efficient manner. In this method, a mixture of the appropriate isatin 6 and an appropriate sulfonyl chloride was stirred with triethylamine in dichloromethane (DCM) at room temperature for 3-24 h under a nitrogen atmosphere. This afforded N-sulfonylisatins 7-18 in 23-86% yields (Scheme 1, Table 1 ). Although this method gave moderate to high yield of the N-sulfonylisatin products, some of the compounds were lost when washing the crude product with methanol as evidenced by TLC. In an attempt to improve upon this, flash column chromatography on silica (ethyl acetate/n-hexane = 1:4) was used to purify the crude product 8 instead. However, this gave only a 3% yield of the pure product 8, and some of the product also co-eluted with isatin despite the good separation of the two species on the TLC plate. This could be explained by the poor solubility of isatin and N-sulfonylisatin 8 in the ethyl acetate/n-hexane mixture. Therefore, washing the crude with methanol was deemed to be the most suitable purification method for the synthesis of Nsulfonylisatins in terms of both time and yield. After the successful synthesis of N-sulfonylisatins 7-18, the ring-opening reactions were performed by reacting Nsulfonylisatins 7-18 with either N,N-dimethylethane-1,2-diamine or N,N-dimethylpropane-1,3-diamine in dichloromethane at room temperature for 1-24 h to afford the novel phenylglyoxamide derivatives 19a-33a in 95-99% yields (Scheme 2, Table 2 ). 
The phenylglyoxamide compounds were then converted to the corresponding ammonium salts by treatment with either HCl or methyl iodide. For the formation of hydrochloride salts 19b-33b, phenylglyoxamide derivatives 19a-33a were treated with 4 M hydrogen chloride/dioxane in dichloromethane or diethyl ether at room temperature for 20 min to 6 h. The yellow reaction mixture was then concentrated in vacuo to remove the solvent and excess hydrogen chloride/dioxane solution, and the precipitated crude product was washed with diethyl ether to remove unreacted phenylglyoxamide starting material, affording the hydrochloride salts 19b-33b in 60-100% yields (Scheme 2, Table 2 ).
Similarly, the synthesis of the iodide salts 19c-33c involved the reaction of phenylglyoxamide derivatives 19a-33a with iodomethane in either dichloromethane or tetrahydrofuran (THF) at room temperature for 14-48 h. The reaction mixture was then concentrated in vacuo to remove the solvent and excess iodomethane, and the precipitated crude product was washed with diethyl ether to remove phenylglyoxamide starting material to afford iodide salts 19c-33c in 63-100% yields (Scheme 2, Table  2 ).
We also investigated the installation of the guanidine group at the end of the glyoxamide chain of analogues, in place of the tertiary or quaternary ammonium group. The first step of the reaction sequence involved the ring-opening of 1-octanesulfonylisatins 9 and 13 and 2-naphthalenesulfonylisatin 15 with tert-butyl N- (3-aminopropyl) carbamate in dichloromethane at room temperature for 15-21 h, which afforded glyoxamide derivatives 34a-36a in 97-98% yields (Scheme 3, Table 3 ). Solutions of the glyoxamide derivatives 34a-36a in dichloromethane were then treated with 4 M hydrogen chloride/dioxane at room temperature for 18 h to cleave the Boc group and liberate the amine functionality. After full conversion of starting material to product, as evidenced by TLC, the solvent and unreacted reagents were removed in vacuo and the residue was washed with diethyl ether to remove traces of starting material and impurities to afford aminoglyoxamide hydrochloride salts 34b-36b in 82-87% yields. 
The aminoglyoxamide hydrochloride salts 34b-36b were converted to the free amine by treatment with 2.5 equivalents of triethylamine, and then reacted with 1.0 equivalent of N,N'-di-Boc-1H-pyrazole-1-carboxamidine in dichloromethane at room temperature for 15-18 h to give the Boc-protected guanidine glyoxamides 34c-36c. The Boc-protected guanidine glyoxamide 34c could be isolated in 33% yield after purification by flash column chromatography on silica, however, analogues 35c-36c were isolated in a very poor yield of 3% using the same procedure (Scheme 4, Table 4 ). We observed that during the synthesis of glyoxamide 35c, a significant amount of white precipitate was found in the reaction mixture, which was removed by filtration before column chromatography. This white precipitate was not observed during the synthesis of analogue 34c. NMR spectroscopy study revealed that the identity of the white precipitate was not the aminoglyoxamide 35b starting material, as evidenced by the absence of a broad amine singlet peak integrating to 2 protons. Moreover, the spectrum of the white precipitate lacked hydrochloride signals. This led to the hypothesis that instead of reacting with N,N'-di-Boc-1H-pyrazole-1-carboxamidine, the terminal amine group of aminoglyoxamide 35b reacted instead with the carbonyl group of the glyoxamide moiety of another molecule of aminoglyoxamide 35b, to form the dimeric imine product 37 ( Figure 4 ). The formation of dimer was confirmed by the high-resolution mass spectrum of the white precipitate, which showed a molecular peak at m/z 939.1939 that was consistent with the molecular formula C38H56Br2N6O6S2Na ([M+Na] + required 939.1941). The corresponding dimeric product could have also been formed in the synthesis of analogue 34c, however, due to its higher solubility in dichloromethane, it may not have precipitated out of the reaction mixture. With the identity of the dimeric side product determined, the reaction conditions (such as solvent, different amount and type of base and amount of N,N'-di-Boc-1H-pyrazole-1-carboxamidine) for the synthesis of 35c were optimised (Table 4 ). The results showed that the use of acetonitrile as a solvent gave the highest yield of product 35c in this reaction. The optimised conditions (Entry 6) were then also applied to aminoglyoxamide 36b, producing Boc-protected guanidine glyoxamide 36c in 36% yield. Table 4 ) Table 4 . Conditions tested for optimising the synthesis of 35c. Finally, Boc-protected guanidine glyoxamides 34c-36c were deprotected by reacting with trifluoroacetic acid in dichloromethane (1:1) at room temperature for 2 h. After the completion of reaction as monitored by TLC, the dichloromethane and excess trifluoroacetic acid were removed in vacuo and impurities were removed by washing the precipitated product with diethyl ether. An ion exchange reaction was then carried out by treating the trifluoroacetate salt with 4 M hydrogen chloride/dioxane in dichloromethane at room temperature for 30 min. Dichloromethane and excess hydrogen chloride/dioxane solution were removed in vacuo and the impurities were again removed by washing the crude solid with diethyl ether to afford the guanidine hydrochloride salts 34d-36d in 67-72% yields.
The overall synthesis of the hydrochloride and iodide salts was achieved in only three steps from isatin and did not require any chromatographic purification. In the first step, Nsulfonylisatins 7-18 were synthesised in moderate to high yields (48-86%) except compounds 14 (32%), 15 (26%) and 17 (23%). These compounds were isolated via washing with methanol and could be used in the next step without further purification. The ring-opening reactions of the N-sulfonylisatins produced glyoxamide derivatives 19a-33a that could be isolated in sufficient purity using simple aqueous work-up. Finally, the salt compounds 19b-33c were also isolated as pure compounds via washing with diethyl ether. For the guanidine series, the intermediates 34-36a and 34b-36b as well as the targeted 34d-36d guanidine hydrochloride salts were all isolated either by filtration with washing or via aqueous work-up. The only compounds that were purified by column chromatography were the Boc-protected guanidine glyoxamides 34c-36c. 1 H NMR was used to confirm the structure of all synthesised compounds, with the presence of the sulfonamide NH proton (δ 10-11) and the glyoxamide NH proton (δ 8-9) being characteristic for compounds of these series. This novel synthetic strategy therefore provides a new and efficient pathway for the synthesis of N-sulfonylisatins and their glyoxamide derivatives, allowing for the development and elucidation of structure-activity relationship (SAR) of glyoxamidebased antibacterial agents.
Antibacterial activity
The antibacterial activity of the synthesised salt compounds 19b-33c and 34d-36d was evaluated by the determination of zone-ofinhibition diameter using the disk diffusion assay and minimum inhibitory concentration (MIC) values from the MIC assay.
Disk diffusion assay
The synthesized compounds 19b-33c and 34d-36d were first screened by using the disk diffusion assays against Staphylococcus aureus (SA38) and Pseudomonas aeruginosa (PAO1). In this assay, bacterial cultures were incubated overnight in tryptone soya broth (TSB) at 37 °C and the resulting bacterial cultures were spread onto nutrient agar plates. The compounds to be tested were administered to sterile 6 mm paper disks at 80 nmol per disk as solutions in DMSO and dried. A well-known antibiotic, gentamicin (0.01 mg per disk) was used as positive control. The diameter of zone of inhibition was measured after incubation at 37 °C for 24 h (Table 5) .
In this assay, active analogues showed zones of inhibition ranging from 7 to 16 mm against S. aureus. The most active compounds against S. aureus in this assay were the guanidine hydrochloride salts 34d and 35d which showed zone of inhibition values of 16 and 15 mm against S. aureus respectively. However, none of the compounds synthesised showed antibacterial activity against the P. aeruginosa strain in the disk diffusion assay.
The antibacterial potency of compounds cannot be determined quantitatively by the disk diffusion assay due to the different diffusion rates of compounds in agar. Therefore, compounds which showed activities in the disk diffusion assay were further analysed by determining their minimum inhibitory concentration (MIC) values.
Minimum inhibitory concentration (MIC) assay
Compounds that showed antibacterial activities in the disk diffusion assay were then tested in the minimum inhibitory concentration assay to quantitatively determine the concentration of compound required to inhibit bacterial growth in liquid media. In this assay, S. aureus SA38 in TSB was incubated with the compounds with final concentration ranging from 8-250 µM at 37 °C for 24 h. The optical density (OD) value at 600 nm was then measured at the end of the 24 h period. The MIC value of each compound was determined as the lowest Table 5 . Zone of inhibition (in mm) and minimum inhibitory concentration (in µM) of compounds against S. aureus (SA38).
Compound
Zone of inhibition [25] concentration that completely inhibited bacterial growth as indicated by an OD value of equal or less than the control with no bacteria (Table 5 ). Among the tested compounds, the guanidine hydrochloride salt 35d showed the lowest MIC value of 12 µM against S. aureus. The antibacterial activity of 35d was comparable with the positive control compound MSI-78, which is a 22-amino acid AMP that is under phase III clinical trials as a topical antibiotic.
[26]
Structure-activity relationship studies
The results of the biological assays were used to investigate the structural-activity relationships of these N-sulfonylphenylglyoxamide-based compounds. Modifying the substituents appended to the ortho sulfonamide group had the greatest influence on the antibacterial activity of a compound. Among all synthesised compounds, only compounds with an octyl group (22a, 22c and 27a-27c) or 2-naphthalenyl group (29a-30c) appended to the ortho sulfonamide group showed antibacterial activity in the disk diffusion assay, whereas compounds with phenyl or tosyl group attached to the sulfonamide group (e.g. 19a-20c and 23a-24c) showed no antibacterial activity. Compounds 32a-33c bearing a butyl chain instead of an octyl chain attached to the sulfonamide group also showed no antibacterial activity in the disk diffusion assay, indicating that a longer alkyl group is preferred Furthermore, the MIC data showed that octanesulfonamide compounds had better antibacterial activity (MIC = 47-250 µM) than the naphthalenesulfonyl compounds (MIC ≥ 250 µM).
Moreover, compounds bearing a bromine substituent at the 5-position of the phenyl ring showed significantly higher antibacterial activities. For instance, 5-Br octyl compounds 27a and 27c showed MIC values of 47 and 63 µM against S. aureus, respectively, meaning that they were at least 4 times more potent than the parent 5-unsubstituted compounds 22a and 22c which both had MIC values of 250 µM (22b was not tested in the MIC assay). Further comparison between compounds indicated that antibacterial ability was diminished once the halogen was removed from the 5-position of the phenyl ring. Specifically, octyl compounds 27a-27c (5-Br), 31a-31c (5-Cl) and 32a-32c (5-F) showed MIC values of 47-94 µM, whereas compounds 22a,c (5-H) and 33a-33c (5-Me) showed MIC values of 125-250 µM. Among the three types of halogen analogues, the bromosubstituted compounds showed higher antibacterial activity compared to the fluoro or chloro compounds.
From the disk diffusion assay (Table 5) , the propylene-linked compounds (22a-c, 27a-c, 30a-30c) showed similar or higher potencies compared to the corresponding ethylene-linked compounds (21a-c, 26a-c, 29a-29c) . However, in the MIC assay, the relationship between linker length and antibacterial activity was less clear (Table 5 ). For example, while the 3-carbon propylene glyoxamide derivative 27a (MIC = 47 µM) was more potent than its corresponding 2-carbon ethylene glyoxamide derivative 26a (MIC = 94 µM), the opposite trend was observed when comparing the 3-carbon propylene glyoxamide derivative 22a (MIC = 250 µM) with the corresponding 2-carbon ethylene glyoxamide derivative 21a (MIC = 63 µM).
From the MIC assay, the glyoxamide derivatives and their corresponding hydrochloride salts and iodide salts showed similar antibacterial activities, with the glyoxamide derivatives having slightly higher potencies than the ionic salts. Interestingly, when a guanidine group was installed at the end of the glyoxamide chain, the antibacterial activities of compounds increased significantly. Compounds 34d and 35d with a guanidine hydrochloride group showed a remarkable improvement (4-5 fold) in antibacterial activity compared to their corresponding glyoxamide derivatives 22a and 27a respectively. In summary, the SAR analysis for these N-sulfonylphenylglyoxamides suggested that having an octyl chain on the sulfonamide group and a 5-bromo substituent at the phenyl ring were the most desirable for antibacterial activity. Moreover, while the glyoxamide amine derivatives showed only slightly higher potencies than the corresponding hydrochloride or methyl iodide salts, compounds with a terminal guanidine hydrochloride group possessed markedly enhanced antibacterial activity. Finally, no significant difference in potency was found between compounds with the 3-carbon propylene linker and those with the 2-carbon ethylene linker.
Membrane conduction
To test how selected potent phenylglyoxamide compounds (27a, 26b, 34d, 35d) might interact with cell membranes, tethered bilayer lipid membrane (tBLM) technology was used in conjunction with electrical impedance spectroscopy.
[22b, 27] By anchoring a lipid membrane onto a gold substrate, it is possible to measure changes in intrinsic membrane conduction in real time upon addition of the compounds. The addition of 30% palmitoyloleoyl-phosphatidylglycerol (POPG) lipids gives the membrane an overall negative charge as would be found in many bacterial cell membranes. Conduction versus concentration graph for the compounds is depicted in Figure 5 . The changes in membrane conduction as a result of adding the molecules were compared to the response of a known pore-forming antimicrobial LL-37. The results showed that high concentrations of phenylglyoxamide compounds could induce an increase in membrane conduction in the tBLM assay. We hypothesize that the compounds might bind to lipid head groups and alter their relative packing density, which induces a change of curvature in lipid morphology into a more curved structure. This could induce lipids to relocate into membrane toroidal pore defects within lipid bilayers, increasing the pore surface area and thereby overall membrane conduction. [29] . However, although the phenylglyoxamide compounds had similar MIC values to LL-37 in the antibacterial assay (MIC = 49 µM), they showed much less activity than LL-37 in the tBLM assay. The increase in membrane conduction was observed only at relatively high concentrations of phenylglyoxamide (≥ 50 μM), whereas for LL-37, an effect on membrane conduction was evident at 1 μM. One reason for the lower activity of the phenylglyoxamides could be that they require a clustering arrangement of compounds into a certain multimeric state in order for pore to form. Regardless of the mechanism, the demonstrated increase in membrane conduction demonstrates the potential of these compounds to act as antimicrobial poreforming agents.
Toxicity assay
The in vitro toxicity of selected potent compounds (26b-c, 27a,  34d, 35d ) was determined against MRC-5 normal human lung fibroblasts using the Alamar blue assay. [30] A dose-response curve for each compound was generated to determine the IC50 values (concentration of compound which reduced cell proliferation by 50% of the vehicle control). The IC50 values which were then used to determine the therapeutic window (IC50 value divided by MIC value), allowing the specificity of the compounds to be ranked ( Figure 6 , Table 6 ). The glyoxamide compound 27a showed a high level of toxicity (IC50 = 37.4 µM) to human cells. This can be explained by the lack of cationic charge at the terminal group of compound 27a. As a consequence, compound 27a has higher hydrophobicity and can more easily bind to the uncharged human cell membrane. Compound 27a showed a therapeutic window of less than 1, meaning that it would be unlikely to be useful as an antibacterial drug.
While the hydrochloride salt 26b and iodide salt 26c had the same values, hydrochloride salt 26b (IC50 = 75.5 µM) showed a higher toxicity towards human cells than the iodide salt 26c (IC50 = 328 µM). Additionally, comparison between the two guanidine hydrochloride salts 34d-35d showed that compound 35d (IC50 = 178 µM) containing the more hydrophobic bromine substituent at the 5-position of the phenyl ring was more toxic than compound 34d (IC50 = 373 µM) which has a hydrogen atom. This suggested that there might be a positive correlation between the hydrophobicity and the toxicity of the compounds towards human cells.
Although the guanidine hydrochloride salt 35d had a relatively low IC50 value compared to compounds 26c and 34d, it also had a significantly lower MIC value which resulted in a higher therapeutic window value. Overall, these data suggest that guanidine hydrochloride salts of glyoxamides could potentially be useful scaffolds for the further development of antimicrobial drugs to treat human bacterial infection.
Conclusions
This study has described an efficient synthetic and purification method for the preparation of N-sulfonylisatins. Twelve Nsulfonylisatins were synthesised, and these were then ringopened with N,N-dimethylethane-1,2-diamine or N,Ndimethylpropane-1,3-diamine, and subsequently converted to hydrochloride or iodide salts to generate a library of 30 novel small molecular AMP mimics. Furthermore, three guanidine hydrochloride mimics were also generated via ring-opening reaction of N-sulfonylisatins with Boc-protected amine, followed by Boc-deprotection and installation of the guanidine moiety. In vitro biological studies of analogues identified that an octyl group appended to ortho sulfonamide group was essential for high antibacterial potency. Moreover, the presence of a halogen at the 5-position of phenyl ring and a terminal guanidine hydrochloride group also enhanced the antibacterial potency of the compounds. Guanidine hydrochloride salt 35d, possessing all three favourable elements, possessed the highest antibacterial potency with an acceptable therapeutic window. Guanidine hydrochloride salt 34d and iodide salt 26c also showed an acceptable therapeutic window despite having lower antibacterial potency. Mechanistically, these compounds could act as antimicrobial pore-forming agents as evidenced by an increase in membrane conduction using a tBLM assay. Thus, this novel class of phenylglyoxamide-based small molecular AMP mimics represents an innovative pathway for the development of novel and cost-effective antimicrobial agents.
Experimental Section Chemistry
All commercially available reagents were purchased from standard suppliers (Sigma Aldrich and Alfa-Aesar) and used without further purification. All reactions were performed under anhydrous condition with an atmosphere of nitrogen and anhydrous solvent unless otherwise specified and anhydrous solvents were obtained using PureSolv MD Solvent Purification System. Reactions were monitored by thin layer chromatography precoated with Merck silica gel 60 F254 and visualization was performed by using short or long wavelength of ultraviolet light. Flash chromatography was carried out using Grace Davisil LC60A silica. Melting points were measured using an OptiMelt melting point apparatus and are uncorrected. 1 H and 13 C NMR spectra were obtained in the specified 
Disk diffusion assay
The disk diffusion method was used to initially evaluate the antibacterial potential of the test compounds against S. aureus (strain 38) and P.
aeruginosa (PAO1). Overnight cultures of bacteria were prepared in tryptone soya broth (TSB; Oxoid, UK) at 37 °C and the resulting bacterial cultures (200 µL) were spread onto nutrient agar plates. The compounds to be tested were dissolved in DMSO and dried on sterile 6 mm diameter paper disks (80 nmol per disk), and placed onto nutrient agar plates. Sterile disks loaded with gentamicin (0.01 mg per disk) were used as positive control. After incubation at 37 °C for 24 h, the diameter of the inhibition zone was measured to the nearest 1.0 mm.
Minimal inhibitory concentration (MIC) assay
Compounds that were shown active from disk diffusion assay were further assessed by determining their minimum inhibitory concentration (MIC)
according to a previously published protocol. [31] A single colony of bacteria was cultured overnight in TSB at 37 °C. The resulting bacterial culture was collected by centrifugation and re-suspended in TSB twice. The optical density (OD) of the resulting culture was adjusted to OD600 = 0.1 in TSB (equivalent to 10 8 colony forming unit (CFU)/mL bacteria), and was further diluted to 10 5 CFU/mL in TSB. 100 µL of the bacterial solution was then added to wells of a 96-well plate containing 100 µL serially diluted compound, with final concentration ranging from 8-250 µM. The plates were then incubated at 37 ˚C for 24 h and the data was recorded by measuring the OD value at 600 nm using a Wallac Victor (Perkin-Elmer) microplate reader. The MIC value of each compound was determined as the lowest concentration that completely inhibited the growth of bacteria.
Each experiment was performed in triplicate and was repeated in two independent experiments.
Tethered bilayer lipid membrane assay
Tethered bilayer lipid membranes (tBLMs) in association with alternating current electrical impedance spectroscopy techniques were employed to determine if the compounds are lytic to cell membranes. Sparsely tethered tBLMs were created using the solvent exchange technique described previously. [32] In short, pre-prepared tethered benzyl-disulfide (tetraethyleneglycol) n = 2 C20-phytanyl tethers benzyl-disulfide-tetraethyleneglycol-OH spacers in the ratio of 1:10 were coated onto a gold 
Toxicity assay
Normal human lung fibroblasts MRC-5 were cultured in minimal essential medium (MEM, Invitrogen) supplemented with 10% foetal calf serum, 2% sodium bicarbonate, 1% L-glutamine-penicillin-streptomycin, 1% non-essential amino acids (NEAA) and 1% sodium pyruvate. The cell line was maintained at 37 °C in 5% CO2 as an adherent monolayer and was passaged upon reaching confluence by standard cell culture techniques. MRC-5 cells were then seeded at 2 × 10 4 cells per well in 96-well plates to ensure full confluence (quiescence). 24 h after seeding, cells were treated with 0.1 to 500 μM of compounds. After 72 h incubation, the treated media was replaced with fresh media containing 10% Alamar blue and the cells were incubated for another 6 h. The metabolic activity was detected by spectrophotometric analysis by assessing the absorbance of Alamar blue as previously described by O'Brien et al. [30] Cell proliferation was determined and expressed as a percentage of untreated control cells. The IC50 values were determined using GraphPad Prism 6.
